American Medical News Examines Clinical Trials Outsourcing

Main Category: Clinical Trials / Drug Trials
Also Included In: Pharma Industry / Biotech Industry
Article Date: 10 Sep 2009 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated

American Medical News examines the ethical considerations of outsourcing pharmaceutical clinical trials to developing countries. The article highlights how it is less expensive for a drug company to conduct a trial in India, where it runs about $2,000 to track a patient through a trial, compared to the cost in the U.S., which is "10 times more." The disparities between participants in the two countries in terms of income, education and access to care are "stark" and the playing field "uneven," writes American Medical News.

While twenty years ago, most U.S. companies conducted clinical trials on their home soil, now "[t]he 20 largest U.S.-based drugmakers conduct about a third of their phase III clinical trials outside the country, and a majority of their study sites also are elsewhere, says a Feb. 19 article in The New England Journal of Medicine," according to American Medical News.

"There are just going to be more people in other parts of the world who are having health issues that need to be addressed and are ready to consent to clinical trials, because really it is the only mechanism for receiving care," said Jill Fisher of Vanderbilt University's Center for Biomedical Ethics and Society. She added that "clinical trials are a problematic kind of care, because it comes in the context of a study intervention. But people are ready to enroll, because they see it as such an incredible advantage over basically nothing."

The article outlines additional concerns about outsourcing clinical trials, such as limited ethical oversight of trials, language barriers, cultural norms and government corruption, as well as comments by other experts on the pros and cons of clinical-trial outsourcing (O'Reilly, 9/7).

This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org.

© Henry J. Kaiser Family Foundation. All rights reserved.



Article adapted by Medical News Today from original press release.
Visit our clinical trials / drug trials section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "American Medical News Examines Clinical Trials Outsourcing." Medical News Today. MediLexicon, Intl., 10 Sep. 2009. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/163539.php>

APA
Kaiser. (2009, September 10). "American Medical News Examines Clinical Trials Outsourcing." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/163539.php.

Please note: If no author information is provided, the source is cited instead.


Clinical Trials / Drug Trials

Most Popular Articles



Follow Our Clinical Trials News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Clinical Trials / Drug Trials Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »